KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Non-Current Deffered Revenue for 18 consecutive years, with $75.7 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Deffered Revenue fell 46.16% year-over-year to $75.7 million; the TTM value through Mar 2026 reached $75.7 million, down 46.16%, while the annual FY2025 figure was $92.0 million, 41.21% down from the prior year.
  • Non-Current Deffered Revenue hit $75.7 million in Q1 2026 for Ionis Pharmaceuticals, down from $92.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $333.1 million in Q1 2022 and bottomed at $75.7 million in Q1 2026.
  • Average Non-Current Deffered Revenue over 5 years is $207.3 million, with a median of $215.1 million recorded in 2024.
  • Year-over-year, Non-Current Deffered Revenue dropped 15.4% in 2023 and then crashed 46.16% in 2026.
  • Ionis Pharmaceuticals' Non-Current Deffered Revenue stood at $287.8 million in 2022, then dropped by 16.19% to $241.2 million in 2023, then tumbled by 35.11% to $156.5 million in 2024, then crashed by 41.21% to $92.0 million in 2025, then decreased by 17.67% to $75.7 million in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $75.7 million, $92.0 million, and $107.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.